INmune Bio announces enrollment of 208 patients in Phase 2 trial of early AD

INmune Bio (INMB) announced that it completed randomization of patients for its Phase 2 trial on Monday, November 11th. This global, blinded, randomized Phase 2 trial is focused on patients with Early AD, Alzheimer’s Disease, and biomarkers of elevated neuroinflammation. “We are excited to have completed administering first doses to all patients enrolled in our phase 2 Alzheimer’s trial,” stated RJ Tesi PhD, the CEO of INmune Bio. “A global trial of this size is a major accomplishment for INmune and is a testament to the hard work and dedication of our team. The trial ended up overenrolled with a total of 208 patients, 56% of whom were categorized as mild AD and 44% as MCI. We look forward to releasing top line cognitive results in the second quarter of 2025.”